Brivaracetam structure
|
Common Name | Brivaracetam | ||
|---|---|---|---|---|
| CAS Number | 357336-20-0 | Molecular Weight | 212.289 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 409.3±28.0 °C at 760 mmHg | |
| Molecular Formula | C11H20N2O2 | Melting Point | 76.38° | |
| MSDS | N/A | Flash Point | 201.3±24.0 °C | |
Use of BrivaracetamBrivaracetam(UCB-34714) is a 4-substituted pyrrolidone butanamide as agent with significant antiepileptic activity; high affinity SV2A ligand and also shows an ability to inhibit Na+ channels. |
| Name | (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide |
|---|---|
| Synonym | More Synonyms |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 409.3±28.0 °C at 760 mmHg |
| Melting Point | 76.38° |
| Molecular Formula | C11H20N2O2 |
| Molecular Weight | 212.289 |
| Flash Point | 201.3±24.0 °C |
| Exact Mass | 212.152481 |
| PSA | 63.40000 |
| LogP | 0.88 |
| Vapour Pressure | 0.0±1.0 mmHg at 25°C |
| Index of Refraction | 1.494 |
| InChIKey | MSYKRHVOOPPJKU-BDAKNGLRSA-N |
| SMILES | CCCC1CC(=O)N(C(CC)C(N)=O)C1 |
| HS Code | 2933990090 |
|---|
|
~%
Brivaracetam CAS#:357336-20-0 |
| Literature: UCB S.A. Patent: WO2007/31263 A1, 2007 ; Location in patent: Page/Page column 31 ; |
|
~%
Brivaracetam CAS#:357336-20-0 |
| Literature: Kenda, Benoit M.; Matagne, Alain C.; Talaga, Patrice E.; Pasau, Patrick M.; Differding, Edmond; Lallemand, Benedicte I.; Frycia, Anne M.; Moureau, Florence G.; Klitgaard, Henrik V.; Gillard, Michel R.; Fuks, Bruno; Michel, Philippe Journal of Medicinal Chemistry, 2004 , vol. 47, # 3 p. 530 - 549 |
| Precursor 2 | |
|---|---|
| DownStream 0 | |
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| Briviact |
| (2S)-2-[(4R)-2-Oxo-4-propyl-1-pyrrolidinyl]butanamide |
| 1-Pyrrolidineacetamide, α-ethyl-2-oxo-4-propyl-, (αS,4R)- |
| Rikelta |
| UCB 34714 |
| UCB34714 |
| Brivaracetam |